Vilazodone Hydrochloride Patent Expiration

Vilazodone Hydrochloride is Used for treating major depressive disorder (MDD). It was first introduced by Abbvie Inc in its drug Viibryd on Jan 21, 2011. 6 different companies have introduced drugs containing Vilazodone Hydrochloride.


Vilazodone Hydrochloride Patents

Given below is the list of patents protecting Vilazodone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Viibryd US7834020

(Pediatric)

Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec 05, 2022

(Expired)

Abbvie
Viibryd US8193195

(Pediatric)

Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec 05, 2022

(Expired)

Abbvie
Viibryd US8236804

(Pediatric)

Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Dec 05, 2022

(Expired)

Abbvie
Viibryd US8673921

(Pediatric)

Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec 05, 2022

(Expired)

Abbvie
Viibryd US7834020 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Jun 05, 2022

(Expired)

Abbvie
Viibryd US8193195 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Jun 05, 2022

(Expired)

Abbvie
Viibryd US8236804 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Jun 05, 2022

(Expired)

Abbvie
Viibryd US8673921 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Jun 05, 2022

(Expired)

Abbvie
Viibryd US5532241 Piperidines and piperazines Sep 29, 2014

(Expired)

Abbvie



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vilazodone Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Vilazodone Hydrochloride.

Activity Date Patent Number
Patent litigations
Expire Patent 08 Jul, 2024 US8193195(Litigated)
Maintenance Fee Reminder Mailed 25 Mar, 2024 US8236804(Litigated)
Maintenance Fee Reminder Mailed 22 Jan, 2024 US8193195(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 04 May, 2022 US7834020(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 01 Sep, 2021 US8673921(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 23 Jan, 2020 US8236804(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 21 Nov, 2019 US8193195(Litigated)
Request for Trial Denied 23 Jul, 2018 US8673921(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 03 May, 2018 US7834020(Litigated)
Petition Requesting Trial 05 Jan, 2018 US8673921(Litigated)


Vilazodone Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Vilazodone Hydrochloride Generics

Several generic applications have been filed for Vilazodone Hydrochloride. The first generic version for Vilazodone Hydrochloride was by Teva Pharmaceuticals Usa and was approved on Sep 30, 2019. And the latest generic version is by Apotex Inc and was approved on Jul 7, 2023.

Given below is the list of companies who have filed for Vilazodone Hydrochloride generic.


1. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Prescription ORAL AB Apr 27, 2021
20MG tablet Prescription ORAL AB Apr 27, 2021
40MG tablet Prescription ORAL AB Apr 27, 2021


2. ALEMBIC

Alembic Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Alembic.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG tablet Prescription ORAL AB Jan 10, 2020
10MG tablet Prescription ORAL AB Jan 10, 2020
40MG tablet Prescription ORAL AB Jan 10, 2020


3. APOTEX

Apotex Inc has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Prescription ORAL AB Jul 7, 2023
20MG tablet Prescription ORAL AB Jul 7, 2023
40MG tablet Prescription ORAL AB Jul 7, 2023


4. INVAGEN PHARMS

Invagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Invagen Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Prescription ORAL AB Apr 7, 2021
40MG tablet Prescription ORAL AB Apr 7, 2021
20MG tablet Prescription ORAL AB Dec 6, 2022


5. TEVA PHARMS USA

Teva Pharmaceuticals Usa has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG tablet Prescription ORAL AB Sep 30, 2019
10MG tablet Prescription ORAL AB Sep 30, 2019
40MG tablet Prescription ORAL AB Sep 30, 2019